SlideShare a Scribd company logo
Asthma
Reactive Airway Disease

Mr. Sanil Varghese
Lecturer
YNC
YU
Definition of Asthma
Chronic inflammatory disorder of the
airways characterized by periods of
reversible bronchospasm.
Chronic inflammation is associated with
airway hyper responsiveness that leads to
recurrent
episodes
of
wheezing,
breathlessness, chest tightness, and
coughing, particularly at night or in the
early morning.
Asthma Triggers
Allergens
Dust mites, mold spores, animal dander,
cockroaches, pollen, indoor and outdoor
pollutants, irritants (smoke, perfumes, cleaning
agents)

Pharmacologic agents (ASA, beta-blockers)
Physical triggers (exercise, cold air)
Physiologic factors
Stress, GERD, viral and bacterial URI, rhinitis
.
Factors that Exacerbate Asthma


Allergens



Respiratory infections



Exercise and hyperventilation



Weather changes



Sulfur dioxide



Food, additives, drugs

© Global Initiative for Asthma
Factors that Influence Asthma
Development and Expression
Host Factors
 Genetic
 - Atopy
 - Airway hyperresponsiveness
 Gender
 Obesity

Environmental Factors
 Indoor allergens
 Outdoor allergens
 Occupational sensitizers
 Tobacco smoke
 Air Pollution
 Respiratory Infections
 Diet
© Global Initiative for Asthma
Asthma Inflammation: Cells and Mediators

Source: Peter J. Barnes, MD
Mechanisms: Asthma Inflammation

Source: Peter J. Barnes, MD
Asthma Inflammation: Cells and Mediators

Source: Peter J. Barnes, MD
Figure 9-10. Bronchospasm clinical scenario (e.g., asthma).
Figure 9-11. Excessive bronchial secretions clinical scenario.
Diagnostic Testing


Peak expiratory flow (PEF)



Inexpensive
Patients can use at home
Diagnostic Testing


Spirometry







Recommended to do spirometry pre- and post- use
of an albuterol MDI to establish reversibility of
airflow obstruction
> 12% reversibility or an increase in FEV1 of
200cc is considered significant
Obstructive pattern: reduced FEV1/FVC ratio
Restrictive pattern: reduced FVC with a normal
FEV1/FVC ratio
Diagnostic Testing


Spirometry


National Asthma Education and Prevention
Program (NAEPP) recommends spirometry:
For initial assessment
 Evaluation of response to treatment
 Assessment of airway function at least every 1-2 years

Diagnostic Testing


Methacholine challenge







Most common bronchoprovocative test in US
Patients breathe in increasing amounts of
methacholine and perform spirometry after each
dose
Increased airway hyperresponsiveness is
established with a 20% or more decrease in FEV1
from baseline at a concentration < 8mg/dl
May miss some cases of exercise-induced asthma
Diagnostic testing


Diagnostic trial of anti-inflammatory
medication (preferably corticosteroids) or an
inhaled bronchodilator




Especially helpful in very young children unable to
cooperate with other diagnostic testing
There is no one single test or measure that can
definitively be used to diagnose asthma in every
patient
Clinical Data Obtained at the
Patient’s Bedside
Vital signs
 Increased respiratory rate
 Increased heart rate, cardiac output,
blood pressure
Clinical Data Obtained at the
Patient’s Bedside









Use of accessory muscles of inspiration
Use of accessory muscles of expiration
Pursed-lip breathing
Substernal intercostal retractions
Increased anteroposterior chest diameter
(barrel chest)
Cyanosis
Cough and sputum production
Clinical Data Obtained at the
Patient’s Bedside
Pulsus paradoxus
 Decreased blood pressure during inspiration
 Increased blood pressure during expiration
Clinical Data Obtained at the
Patient’s Bedside
Chest assessment findings
 Expiratory prolongation
 Decreased tactile and vocal fremitus
 Hyperresonant percussion
 Diminished breath sounds
 Diminished heart sounds
 Wheezing and rhonchi
Figure 2-12. Percussion becomes more hyperresonant with alveolar hyperinflation.
Figure 2-17. As air trapping and alveolar hyperinflation develop in obstructive lung
diseases, breath sounds progressively diminish.
Pulmonary Function Study:
Expiratory Maneuver Findings
FVC

FEVT

↓

↓

PEFR MVV
↓

↓

FEF25%-75%

FEF200-1200

↓
FEF50%
↓

↓
FEV1%

↓
Pulmonary Function Study:
Lung Volume and Capacity
Findings
VT

RV

FRC

N or ↑

↑

↑

VC

IC
↓

ERV
N or ↓

TLC
N or ↑

RV/TLC ratio
N or ↓

↑
Arterial Blood Gases
Mild to Moderate Asthma Episode


Acute alveolar hyperventilation with hypoxemia

pH

PaCO2

↑

↓

HCO3↓ (Slightly)

PaO2
↓
Arterial Blood Gases
Severe Asthmatic Episode (Status Asthmaticus)


Acute ventilatory failure with hypoxemia

pH
↓

PaCO2

HCO3↓

PaO2
↓ (Significantly)

↓
Abnormal Laboratory Tests and
Procedures


Abnormal laboratory tests and procedures


Sputum examination
Eosinophils
 Charcot-Leyden crystals (see next slide)
 Casts of mucus from small airways






called Kirschman spirals

IgE level (elevated in extrinsic asthma)
Charcot-Leyden Crystals

Needle shaped crystals Represents breakdown products of
eosinophils
Radiologic Findings
Chest radiograph
 Increased anteroposterior diameter
 Translucent (dark) lung fields
 Depressed or flattened diaphragm
Figure 13-4. Chest X-ray of a 2-year-old patient during an acute asthma attack.
Asthma Classification Based on
Severity—Excerpts
Disease
Step 4:
Step 3:
Step 2:
Step 1:

Symptoms
Continual symptoms
Daily symptoms
Symptoms > than twice weekly
Symptoms < than twice weekly

From McCance KL, Huether SE: Pathophysiology: The biologic basis for disease in adults and children, ed 4,
St. Louis, 2002, Mosby.
Asthma Zone Management System
—Excerpts


Green zone




Yellow zone




80% to 100% of personal best PEFR
50% to 80% of personal best PEFR

Red zone


<50% of personal best PEFR
Pharmacologic Therapy


Long-term control medications


Corticosteroids
inhaled form
 systemic steroids used to gain prompt control of disease
when initiating inhaled treatment




Cromolyn sodium or Nedocromil
mild-to-moderate anti-inflammatory medications (may
be used initially in children)
 preventive treatment prior to exercise or unavoidable
exposure to known allergens



Long-term control medications


Long-acting beta2-agonists
used concomitantly with anti-inflammatory meds for
long-term symptom control especially nocturnal
symptoms
 prevents exercise-induced bronchospasm




Methylxanthines


sustained-release theophylline used as adjuvant to
inhaled steroids for prevention of nocturnal symptoms


Long-term control medications


Leukotriene modifiers
zafirlukast - leukotriene receptor antagonist
 zileuton - 5-lipoxygenase inhibitor is alternative therapy
to low doses of inhaled steroids/nedocromil/cromolyn
 alternative tx to low dose inhaled
steroids/cromolyn/nedocromil
 recommended for >12yrs with mild persistent asthma.
Further study needed



Quick relief medications






Short acting beta2-agonists - relief of acute
symptoms
Anticholinergics - may provide additive benefit to
beta2 drugs in severe exacerbation. May be
alternative to beta2-agonists
Systemic steroids - moderate-to-severe persistent
asthma in acute exacerbations or to prevent
recurrence of exacerbations
Treatment/Long Term Control


Corticosteroids





Most potent and effective
Reduction in symptoms, improvement in PEF and
spirometry, diminished airway
hyperresponsiveness, prevention of exacerbations,
possible prevention of airway wall remodeling
Suppresses: cytosine production, airway
eosinophilic recruitment, chemical mediators


Corticosteroids





Dose dependent on product and delivery device
2 X/day use is common in moderate-to-severe
persistent asthma
1 or 2 X/day may be used in mild persistent asthma


Cromolyn & nedocromil



Have distinctive properties
Similar anti-inflammatory reactions
blocks Cl - channels
 modulate mast cell mediator release
 modulate eosinophilic recruitment
 inhibits early and late asthmatic response to antigen
challenge



Cromolyn & nedocromil


Similar anti-inflammatory reactions
inhibits bronchospasm (exercise, cold dry air,
bradykinin aerosol)
 nedocromil more potent in inhibiting bronchospasm in
the above situations




Both reduce asthma symptoms
improve PF
 reduce need for short acting beta2 agonists



Long-acting beta-2 agonists





Relax airway smooth muscle
Duration of action >12 hrs
Not used in acute exacerbations
Adjunct to anti-inflammatory tx for long-term
symptom control especially nocturnal symptoms


Methylxanthines






Provides mild-moderate bronchodilation
Low dose has mild anti-inflammatory action
Sustained release form used as alternative but not
preferred to long-acting beta2 agonists to control
nocturnal symptoms
Use may be necessary because of cost or patient
compliance


Leukotriene modifiers


Leukotrienes are potent biochemical mediators
released from mast cells, eosinophils, and
basophils that:
contract bronchial smooth muscle
 increase vascular permeability
 increase mucus secretions
 attract & activate inflammatory cells in airways



Leukotriene modifiers


Zafirlukast & zileuton (oral tabs)








improves lung fx and diminishes symptoms & need for
short-acting beta2 agonists

Studies in mild-moderate asthma showing modest
improvements
Alternative to low-dose inhaled steroids for pts.
with mild persistent asthma
Further study in of other groups needed


Leukotriene modifiers


Zafirlukast - leuktriene receptor antagonist
attenuates late response to inhaled allergen and postallergen induced bronchospasm
 modest improvement in FEV (11% > placebo)
1


improved symptoms
 reduced albuterol use




Warning - increases warfarin half-life and PT &
PTT must be monitored with dose adjustment
when indicated


Leukotriene modifiers


Zileuton - 5-lipoxygenase inhibitor
provides immediate & sustained improvement in FEV1
(mean 15% > placebo) in mild-to-moderate asthma
 moderate asthmatics had fewer exacerbations requiring
oral steroids
 attenuates bronchospasm from exercise & from aspirin
in sensitive people
 inhibits metabolism of theophylline, warfarin,
terfenadine and must be monitored

Asthma Treatment/Quick Relief


Short-acting beta2 agonists








Relax airway smooth muscle and increase in
airflow in <30 minutes
Drug of choice for treating symptoms and
exacerbations and EIB
Use of >1 canister/mo indicates inadequate
control and indicates need to intensify antiinflammatory tx
Regularly scheduled use NOT recommended


Anticholinergics








Cholinergic innervation important in regulation of
airway smooth muscle tone
Ipratropium bromide (quaternary derivative of
atropine without its’ side effects)
Additive benefit with inhaled beta 2-agonists in
severe asthma exacerbations
Effectiveness in long-term management not
demonstrated
Intermittent Asthma


Step 1


Short-acting inhaled beta 2 agonists PRN




IF NEEDED >2 X/wk PATIENT SHOULD BE
MOVED TO THE NEXT STEP OF CARE
(exception is EIB or viral infections)

Viral infections
mild symptoms - beta 2 agonist Q 4-6 hr
 moderate-to-severe symptoms - short course of systemic
steroids recommended plus above

Persistent Asthma


Mild, moderate or severe




Daily long-term control recommended

Mild persistent asthma (step 2 care)




Daily anti-inflammatory meds - inhaled steroids
(low dose) or cromolyn or nedocromil
Sustained release theophylline alternative but not
preferred


Mild persistent asthma (step 2 care)



Zafirlukast or zileuton considered in pts. >12 yrs
Quick relief medications must be available


short-acting beta 2 agonists



intensity depends upon severity of exacerbation


Moderate persistent asthma (step 3 care)
Increase inhaled steroids to medium dose
OR
 Add long-acting bronchodilator to a low-medium
dose of inhaled steroids
OR
 Increase to medium dose steroid then lower dose &
add nedocromil (+/-)



Moderate persistent asthma (if not adequately
controlled)


Increase to high dose inhaled steroids & add longacting bronchodilator (serevent or theophylline)


Severe persistent asthma (step 4)


If not controlled on high dose of inhaled steroids
and long-acting bronchodilator ADD oral
systemic steroids on a regularly scheduled, longterm basis
use lowest dose
 monitor closely
 attempt to reduce or take off when control established

Emergency Department
Treatment




Start treatment when asthma exacerbation
recognized
While treatment is being given:




Take a more detailed history
Complete physical examination
Perform laboratory studies


PEF on presentation, after initial tx. and at frequent
intervals)


Perform laboratory studies
FEV1 or PEF <50% pred. then assess oxygenation by
pulse oximetry
 Lab studies will vary with situation (CBC, electrolytes,
serum theophylline level. CXR, ECG). These lab
studies are NOT routinely recommended



Treatment:


O2 (Sa O2 90-95),

inhaled short-acting bronchodilator for all pts. (3 tx Q
20 min, continuous therapy an option)
 Consider anti-cholinergics
 oral systemic corticosteroids (unresponsive to initial
beta2 agonist therapy, moderate-to-severe asthma,
people who are on steroids)
 systemic steroids administered when admitted
 methylxanthines are not recommended



Treatment:
Aggressive hydration NOT recommended for older
children and adults (may be necessary with infants and
sm. children)
 Antibiotics NOT recommended unless infection present
(fever, purulent sputum)
 CPT NOT recommended
 Mucolytics NOT recommended
 Sedation NOT recommended

Long-Term, Control
Medications

Decrease the inflammation/swelling

Advair
Quick R
elief Medications
Loosens your muscles & stops the wheezing

Albuterol for
Nebulizer
Spacers
Without Spacer

©1998,
Respironics Inc.

With Spacer
Why Control Asthma?
•Mild intermittent
•Mild persistent
•Moderate persistent
•Severe persistent

More Related Content

PPTX
Asthma
Reynel Dan
 
PPTX
Asthma
Akhil Raj
 
PPTX
Bronchial Asthma by Dr. Sookun Rajeev Kumar
Dr. Sookun Rajeev Kumar
 
PPTX
Bronchial Asthma: Definition,Pathophysiology and Management
Marko Makram
 
PPT
Asthma
Richin Koshy
 
PDF
Bronchial asthma
Hamdi Turkey
 
Asthma
Reynel Dan
 
Asthma
Akhil Raj
 
Bronchial Asthma by Dr. Sookun Rajeev Kumar
Dr. Sookun Rajeev Kumar
 
Bronchial Asthma: Definition,Pathophysiology and Management
Marko Makram
 
Asthma
Richin Koshy
 
Bronchial asthma
Hamdi Turkey
 

What's hot (20)

PPTX
Bronchial asthama
Shyam Bhatewara
 
PPT
ASTHMA
Aman Baloch
 
PPT
Bronchial Asthma
Eneutron
 
PPTX
Pneumonia
Eko Priyanto
 
PPTX
Asthma
Hardik Vora
 
PPTX
Bronchial asthma
Dr. Rana Shankor Roy
 
PPTX
COPD
hawraz Faris
 
PPTX
Pneumonia
Rahul Arya
 
PPTX
Bronchial asthma management
Sameh Abdel-ghany
 
PPTX
pneumonia ppt
saif ali khan
 
PDF
Pneumonia
Shirajam Munir Sweet
 
PPT
Asthma ppt
Andhrapradesh
 
PPT
Bronchial Asthma Presentation.
Michael Kino
 
PPT
classification of pnemonia
Dr Harikrishna Harindran
 
PPTX
Asthma
Laith Albazooni
 
PPTX
Pneumonia
Firoz Hakkim
 
PPTX
Pneumonia
Abhishek Achar
 
PPTX
pathophysiology of asthma and COPD
Dr. Koppala R.V.S. Chaitanya
 
PDF
Emphysema
Prasad CSBR
 
Bronchial asthama
Shyam Bhatewara
 
ASTHMA
Aman Baloch
 
Bronchial Asthma
Eneutron
 
Pneumonia
Eko Priyanto
 
Asthma
Hardik Vora
 
Bronchial asthma
Dr. Rana Shankor Roy
 
Pneumonia
Rahul Arya
 
Bronchial asthma management
Sameh Abdel-ghany
 
pneumonia ppt
saif ali khan
 
Asthma ppt
Andhrapradesh
 
Bronchial Asthma Presentation.
Michael Kino
 
classification of pnemonia
Dr Harikrishna Harindran
 
Pneumonia
Firoz Hakkim
 
Pneumonia
Abhishek Achar
 
pathophysiology of asthma and COPD
Dr. Koppala R.V.S. Chaitanya
 
Emphysema
Prasad CSBR
 
Ad

Similar to Asthma (20)

PPTX
Asthma education for school students and value education
Aravind Alagarsamy
 
PPTX
Microsoft+PowerPoint+-+Asthma+4th+year+Lecture+(1)+[Compatibility+Mode].pptx
Fekadu50
 
PPT
Asthma
Dr UAK
 
PPTX
25.3456 Bronchial asthma Pulmonology.pptx
PANFRAGGER
 
PDF
Microsoft PowerPoint - Asthma 4th year Lecture (1) [Compatibility Mode].pdf
AmanuelMamuye1
 
PPTX
B'asthma -LECTURE.pptx
Stano3
 
PPTX
Asthma management 2
Mujahid Chandio
 
PPT
Unit_6_Asthma_Overview.ppt prevention diagnosis
palanivelleena
 
PPTX
Asthma .pptx
UVAS
 
PPTX
ASTHMA etiology, risk factors, pathophysiology and it's management
PoovarasanA5
 
PPT
196266.ppt presentation about bronchial asthma
DanaYrzabek
 
PPTX
Bronchial Asthma, diagnosis and treatment
Mohammed Ahmed Bamashmos
 
PDF
asthma Etiology/ pathophysiology /Diagnosis M
Dr. Mohammad Abas Reshi
 
PPTX
Asthma in the Emergency Room Presentation.pptx
Tinowimba
 
PPTX
BRONCHIAL ASTHMA.pptx
rajendra gopal
 
PPT
Asthma causes treatment and oxygen theraphy
AhmadUllah71
 
PPTX
Bronchial Asthma new ppt04.pptx including
RashmitaDahal
 
PPTX
Airways obstruction (Bronchial Asthma).pptx
Zubbi1
 
PPTX
Bronchial asthma
Mahamad Jamal
 
PPTX
Lec.5 - Asthma.pptx
AliAlHazaimeh
 
Asthma education for school students and value education
Aravind Alagarsamy
 
Microsoft+PowerPoint+-+Asthma+4th+year+Lecture+(1)+[Compatibility+Mode].pptx
Fekadu50
 
Asthma
Dr UAK
 
25.3456 Bronchial asthma Pulmonology.pptx
PANFRAGGER
 
Microsoft PowerPoint - Asthma 4th year Lecture (1) [Compatibility Mode].pdf
AmanuelMamuye1
 
B'asthma -LECTURE.pptx
Stano3
 
Asthma management 2
Mujahid Chandio
 
Unit_6_Asthma_Overview.ppt prevention diagnosis
palanivelleena
 
Asthma .pptx
UVAS
 
ASTHMA etiology, risk factors, pathophysiology and it's management
PoovarasanA5
 
196266.ppt presentation about bronchial asthma
DanaYrzabek
 
Bronchial Asthma, diagnosis and treatment
Mohammed Ahmed Bamashmos
 
asthma Etiology/ pathophysiology /Diagnosis M
Dr. Mohammad Abas Reshi
 
Asthma in the Emergency Room Presentation.pptx
Tinowimba
 
BRONCHIAL ASTHMA.pptx
rajendra gopal
 
Asthma causes treatment and oxygen theraphy
AhmadUllah71
 
Bronchial Asthma new ppt04.pptx including
RashmitaDahal
 
Airways obstruction (Bronchial Asthma).pptx
Zubbi1
 
Bronchial asthma
Mahamad Jamal
 
Lec.5 - Asthma.pptx
AliAlHazaimeh
 
Ad

More from Sanil Varghese (20)

PPTX
Traction
Sanil Varghese
 
PPTX
Splints
Sanil Varghese
 
PPTX
Prosthetics
Sanil Varghese
 
PPTX
Plaster casts
Sanil Varghese
 
PPTX
Osteoporosis
Sanil Varghese
 
PPT
Orthopedics radiography sanil
Sanil Varghese
 
PPTX
Orthopedic implants
Sanil Varghese
 
PPTX
Orthopedic beds
Sanil Varghese
 
PPTX
Myopathies
Sanil Varghese
 
PPTX
Musculoskeletal
Sanil Varghese
 
PPTX
Musculo skeletal disorders
Sanil Varghese
 
PPTX
Gout
Sanil Varghese
 
PPT
Fractures
Sanil Varghese
 
PPTX
Braces
Sanil Varghese
 
PPTX
Bones
Sanil Varghese
 
PPTX
Bone tumors
Sanil Varghese
 
PPTX
Peripheral nerve disorders
Sanil Varghese
 
PPT
Myasthenia gravis new
Sanil Varghese
 
PPTX
Meningitis
Sanil Varghese
 
PPTX
Cranial nerve disorders
Sanil Varghese
 
Traction
Sanil Varghese
 
Prosthetics
Sanil Varghese
 
Plaster casts
Sanil Varghese
 
Osteoporosis
Sanil Varghese
 
Orthopedics radiography sanil
Sanil Varghese
 
Orthopedic implants
Sanil Varghese
 
Orthopedic beds
Sanil Varghese
 
Myopathies
Sanil Varghese
 
Musculoskeletal
Sanil Varghese
 
Musculo skeletal disorders
Sanil Varghese
 
Fractures
Sanil Varghese
 
Bone tumors
Sanil Varghese
 
Peripheral nerve disorders
Sanil Varghese
 
Myasthenia gravis new
Sanil Varghese
 
Meningitis
Sanil Varghese
 
Cranial nerve disorders
Sanil Varghese
 

Recently uploaded (20)

PPTX
Drug hypersensitivity Prof Ghada Shousha, Assistant Professor of pediatrics, ...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
 
PPT
9. Applied Biomechanics (fracture fixation)etc.ppt
Bolan University of Medical and Health Sciences ,Quetta
 
PDF
Consult Best Sexologist Patna Bihar Vascular ED Problems Dr Sunil Dubey
Sexologist Dr. Sunil Dubey - Dubey Clinic
 
PPTX
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
Shivankan Kakkar
 
PDF
Consanguineous Marriages: A Multidisciplinary Analysis of Sociocultural, Gene...
GAURAV. H .TANDON
 
PDF
Noble Metals and Base Metals in Prosthodontics
Praveen Prabu
 
PPTX
Transfusion of Blood Components – A Guide for Nursing Faculty.pptx
AbrarKabir3
 
PPTX
Nirsevimab in India - Single-Dose Monoclonal Antibody to Combat RSV .pptx
Gaurav Gupta
 
DOCX
RUHS II MBBS Pharmacology Paper-I with Answer Key | 26 July 2025 (New Scheme)
Shivankan Kakkar
 
PPTX
The Anatomy of the Major Salivary Glands
Srinjoy Chatterjee
 
PPTX
Temperature Mapping in Pharmaceutical.pptx
Shehar Bano
 
PDF
Bassem Matta, CCMA
Smiling Lungs
 
PPTX
perioperative management and ERAS protocol.pptx
Fahad Ahmad
 
PPTX
TOC sampling methods for cleaning validation
Markus Janssen
 
PPTX
13.Anesthesia and its all types.....pptx
Bolan University of Medical and Health Sciences ,Quetta
 
PPTX
Describe Thyroid storm & it’s Pharmacotherapy Drug Interaction: Pyridoxine + ...
Dr. Deepa Singh Rana
 
PPTX
CANSA Womens Health UTERINE focus Top Cancers slidedeck Aug 2025
CANSA The Cancer Association of South Africa
 
PDF
Writing and Teaching as Personal Documentation of Continuing Professional Dev...
Robertus Arian Datusanantyo
 
PPTX
Anatomy of eyelids basic anatomy covered along with abnormalities of eyelids
SummyBhatnagar1
 
PPTX
12. Biomechanicsof the humanlowerextremity.pptx
Bolan University of Medical and Health Sciences ,Quetta
 
Drug hypersensitivity Prof Ghada Shousha, Assistant Professor of pediatrics, ...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
 
9. Applied Biomechanics (fracture fixation)etc.ppt
Bolan University of Medical and Health Sciences ,Quetta
 
Consult Best Sexologist Patna Bihar Vascular ED Problems Dr Sunil Dubey
Sexologist Dr. Sunil Dubey - Dubey Clinic
 
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
Shivankan Kakkar
 
Consanguineous Marriages: A Multidisciplinary Analysis of Sociocultural, Gene...
GAURAV. H .TANDON
 
Noble Metals and Base Metals in Prosthodontics
Praveen Prabu
 
Transfusion of Blood Components – A Guide for Nursing Faculty.pptx
AbrarKabir3
 
Nirsevimab in India - Single-Dose Monoclonal Antibody to Combat RSV .pptx
Gaurav Gupta
 
RUHS II MBBS Pharmacology Paper-I with Answer Key | 26 July 2025 (New Scheme)
Shivankan Kakkar
 
The Anatomy of the Major Salivary Glands
Srinjoy Chatterjee
 
Temperature Mapping in Pharmaceutical.pptx
Shehar Bano
 
Bassem Matta, CCMA
Smiling Lungs
 
perioperative management and ERAS protocol.pptx
Fahad Ahmad
 
TOC sampling methods for cleaning validation
Markus Janssen
 
13.Anesthesia and its all types.....pptx
Bolan University of Medical and Health Sciences ,Quetta
 
Describe Thyroid storm & it’s Pharmacotherapy Drug Interaction: Pyridoxine + ...
Dr. Deepa Singh Rana
 
CANSA Womens Health UTERINE focus Top Cancers slidedeck Aug 2025
CANSA The Cancer Association of South Africa
 
Writing and Teaching as Personal Documentation of Continuing Professional Dev...
Robertus Arian Datusanantyo
 
Anatomy of eyelids basic anatomy covered along with abnormalities of eyelids
SummyBhatnagar1
 
12. Biomechanicsof the humanlowerextremity.pptx
Bolan University of Medical and Health Sciences ,Quetta
 

Asthma

  • 1. Asthma Reactive Airway Disease Mr. Sanil Varghese Lecturer YNC YU
  • 2. Definition of Asthma Chronic inflammatory disorder of the airways characterized by periods of reversible bronchospasm. Chronic inflammation is associated with airway hyper responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning.
  • 3. Asthma Triggers Allergens Dust mites, mold spores, animal dander, cockroaches, pollen, indoor and outdoor pollutants, irritants (smoke, perfumes, cleaning agents) Pharmacologic agents (ASA, beta-blockers) Physical triggers (exercise, cold air) Physiologic factors Stress, GERD, viral and bacterial URI, rhinitis
  • 4. .
  • 5. Factors that Exacerbate Asthma  Allergens  Respiratory infections  Exercise and hyperventilation  Weather changes  Sulfur dioxide  Food, additives, drugs © Global Initiative for Asthma
  • 6. Factors that Influence Asthma Development and Expression Host Factors  Genetic  - Atopy  - Airway hyperresponsiveness  Gender  Obesity Environmental Factors  Indoor allergens  Outdoor allergens  Occupational sensitizers  Tobacco smoke  Air Pollution  Respiratory Infections  Diet © Global Initiative for Asthma
  • 7. Asthma Inflammation: Cells and Mediators Source: Peter J. Barnes, MD
  • 9. Asthma Inflammation: Cells and Mediators Source: Peter J. Barnes, MD
  • 10. Figure 9-10. Bronchospasm clinical scenario (e.g., asthma).
  • 11. Figure 9-11. Excessive bronchial secretions clinical scenario.
  • 12. Diagnostic Testing  Peak expiratory flow (PEF)   Inexpensive Patients can use at home
  • 13. Diagnostic Testing  Spirometry     Recommended to do spirometry pre- and post- use of an albuterol MDI to establish reversibility of airflow obstruction > 12% reversibility or an increase in FEV1 of 200cc is considered significant Obstructive pattern: reduced FEV1/FVC ratio Restrictive pattern: reduced FVC with a normal FEV1/FVC ratio
  • 14. Diagnostic Testing  Spirometry  National Asthma Education and Prevention Program (NAEPP) recommends spirometry: For initial assessment  Evaluation of response to treatment  Assessment of airway function at least every 1-2 years 
  • 15. Diagnostic Testing  Methacholine challenge     Most common bronchoprovocative test in US Patients breathe in increasing amounts of methacholine and perform spirometry after each dose Increased airway hyperresponsiveness is established with a 20% or more decrease in FEV1 from baseline at a concentration < 8mg/dl May miss some cases of exercise-induced asthma
  • 16. Diagnostic testing  Diagnostic trial of anti-inflammatory medication (preferably corticosteroids) or an inhaled bronchodilator   Especially helpful in very young children unable to cooperate with other diagnostic testing There is no one single test or measure that can definitively be used to diagnose asthma in every patient
  • 17. Clinical Data Obtained at the Patient’s Bedside Vital signs  Increased respiratory rate  Increased heart rate, cardiac output, blood pressure
  • 18. Clinical Data Obtained at the Patient’s Bedside        Use of accessory muscles of inspiration Use of accessory muscles of expiration Pursed-lip breathing Substernal intercostal retractions Increased anteroposterior chest diameter (barrel chest) Cyanosis Cough and sputum production
  • 19. Clinical Data Obtained at the Patient’s Bedside Pulsus paradoxus  Decreased blood pressure during inspiration  Increased blood pressure during expiration
  • 20. Clinical Data Obtained at the Patient’s Bedside Chest assessment findings  Expiratory prolongation  Decreased tactile and vocal fremitus  Hyperresonant percussion  Diminished breath sounds  Diminished heart sounds  Wheezing and rhonchi
  • 21. Figure 2-12. Percussion becomes more hyperresonant with alveolar hyperinflation.
  • 22. Figure 2-17. As air trapping and alveolar hyperinflation develop in obstructive lung diseases, breath sounds progressively diminish.
  • 23. Pulmonary Function Study: Expiratory Maneuver Findings FVC FEVT ↓ ↓ PEFR MVV ↓ ↓ FEF25%-75% FEF200-1200 ↓ FEF50% ↓ ↓ FEV1% ↓
  • 24. Pulmonary Function Study: Lung Volume and Capacity Findings VT RV FRC N or ↑ ↑ ↑ VC IC ↓ ERV N or ↓ TLC N or ↑ RV/TLC ratio N or ↓ ↑
  • 25. Arterial Blood Gases Mild to Moderate Asthma Episode  Acute alveolar hyperventilation with hypoxemia pH PaCO2 ↑ ↓ HCO3↓ (Slightly) PaO2 ↓
  • 26. Arterial Blood Gases Severe Asthmatic Episode (Status Asthmaticus)  Acute ventilatory failure with hypoxemia pH ↓ PaCO2 HCO3↓ PaO2 ↓ (Significantly) ↓
  • 27. Abnormal Laboratory Tests and Procedures  Abnormal laboratory tests and procedures  Sputum examination Eosinophils  Charcot-Leyden crystals (see next slide)  Casts of mucus from small airways    called Kirschman spirals IgE level (elevated in extrinsic asthma)
  • 28. Charcot-Leyden Crystals Needle shaped crystals Represents breakdown products of eosinophils
  • 29. Radiologic Findings Chest radiograph  Increased anteroposterior diameter  Translucent (dark) lung fields  Depressed or flattened diaphragm
  • 30. Figure 13-4. Chest X-ray of a 2-year-old patient during an acute asthma attack.
  • 31. Asthma Classification Based on Severity—Excerpts Disease Step 4: Step 3: Step 2: Step 1: Symptoms Continual symptoms Daily symptoms Symptoms > than twice weekly Symptoms < than twice weekly From McCance KL, Huether SE: Pathophysiology: The biologic basis for disease in adults and children, ed 4, St. Louis, 2002, Mosby.
  • 32. Asthma Zone Management System —Excerpts  Green zone   Yellow zone   80% to 100% of personal best PEFR 50% to 80% of personal best PEFR Red zone  <50% of personal best PEFR
  • 33. Pharmacologic Therapy  Long-term control medications  Corticosteroids inhaled form  systemic steroids used to gain prompt control of disease when initiating inhaled treatment   Cromolyn sodium or Nedocromil mild-to-moderate anti-inflammatory medications (may be used initially in children)  preventive treatment prior to exercise or unavoidable exposure to known allergens 
  • 34.  Long-term control medications  Long-acting beta2-agonists used concomitantly with anti-inflammatory meds for long-term symptom control especially nocturnal symptoms  prevents exercise-induced bronchospasm   Methylxanthines  sustained-release theophylline used as adjuvant to inhaled steroids for prevention of nocturnal symptoms
  • 35.  Long-term control medications  Leukotriene modifiers zafirlukast - leukotriene receptor antagonist  zileuton - 5-lipoxygenase inhibitor is alternative therapy to low doses of inhaled steroids/nedocromil/cromolyn  alternative tx to low dose inhaled steroids/cromolyn/nedocromil  recommended for >12yrs with mild persistent asthma. Further study needed 
  • 36.  Quick relief medications    Short acting beta2-agonists - relief of acute symptoms Anticholinergics - may provide additive benefit to beta2 drugs in severe exacerbation. May be alternative to beta2-agonists Systemic steroids - moderate-to-severe persistent asthma in acute exacerbations or to prevent recurrence of exacerbations
  • 37. Treatment/Long Term Control  Corticosteroids    Most potent and effective Reduction in symptoms, improvement in PEF and spirometry, diminished airway hyperresponsiveness, prevention of exacerbations, possible prevention of airway wall remodeling Suppresses: cytosine production, airway eosinophilic recruitment, chemical mediators
  • 38.  Corticosteroids    Dose dependent on product and delivery device 2 X/day use is common in moderate-to-severe persistent asthma 1 or 2 X/day may be used in mild persistent asthma
  • 39.  Cromolyn & nedocromil   Have distinctive properties Similar anti-inflammatory reactions blocks Cl - channels  modulate mast cell mediator release  modulate eosinophilic recruitment  inhibits early and late asthmatic response to antigen challenge 
  • 40.  Cromolyn & nedocromil  Similar anti-inflammatory reactions inhibits bronchospasm (exercise, cold dry air, bradykinin aerosol)  nedocromil more potent in inhibiting bronchospasm in the above situations   Both reduce asthma symptoms improve PF  reduce need for short acting beta2 agonists 
  • 41.  Long-acting beta-2 agonists     Relax airway smooth muscle Duration of action >12 hrs Not used in acute exacerbations Adjunct to anti-inflammatory tx for long-term symptom control especially nocturnal symptoms
  • 42.  Methylxanthines     Provides mild-moderate bronchodilation Low dose has mild anti-inflammatory action Sustained release form used as alternative but not preferred to long-acting beta2 agonists to control nocturnal symptoms Use may be necessary because of cost or patient compliance
  • 43.  Leukotriene modifiers  Leukotrienes are potent biochemical mediators released from mast cells, eosinophils, and basophils that: contract bronchial smooth muscle  increase vascular permeability  increase mucus secretions  attract & activate inflammatory cells in airways 
  • 44.  Leukotriene modifiers  Zafirlukast & zileuton (oral tabs)     improves lung fx and diminishes symptoms & need for short-acting beta2 agonists Studies in mild-moderate asthma showing modest improvements Alternative to low-dose inhaled steroids for pts. with mild persistent asthma Further study in of other groups needed
  • 45.  Leukotriene modifiers  Zafirlukast - leuktriene receptor antagonist attenuates late response to inhaled allergen and postallergen induced bronchospasm  modest improvement in FEV (11% > placebo) 1  improved symptoms  reduced albuterol use   Warning - increases warfarin half-life and PT & PTT must be monitored with dose adjustment when indicated
  • 46.  Leukotriene modifiers  Zileuton - 5-lipoxygenase inhibitor provides immediate & sustained improvement in FEV1 (mean 15% > placebo) in mild-to-moderate asthma  moderate asthmatics had fewer exacerbations requiring oral steroids  attenuates bronchospasm from exercise & from aspirin in sensitive people  inhibits metabolism of theophylline, warfarin, terfenadine and must be monitored 
  • 47. Asthma Treatment/Quick Relief  Short-acting beta2 agonists     Relax airway smooth muscle and increase in airflow in <30 minutes Drug of choice for treating symptoms and exacerbations and EIB Use of >1 canister/mo indicates inadequate control and indicates need to intensify antiinflammatory tx Regularly scheduled use NOT recommended
  • 48.  Anticholinergics     Cholinergic innervation important in regulation of airway smooth muscle tone Ipratropium bromide (quaternary derivative of atropine without its’ side effects) Additive benefit with inhaled beta 2-agonists in severe asthma exacerbations Effectiveness in long-term management not demonstrated
  • 49. Intermittent Asthma  Step 1  Short-acting inhaled beta 2 agonists PRN   IF NEEDED >2 X/wk PATIENT SHOULD BE MOVED TO THE NEXT STEP OF CARE (exception is EIB or viral infections) Viral infections mild symptoms - beta 2 agonist Q 4-6 hr  moderate-to-severe symptoms - short course of systemic steroids recommended plus above 
  • 50. Persistent Asthma  Mild, moderate or severe   Daily long-term control recommended Mild persistent asthma (step 2 care)   Daily anti-inflammatory meds - inhaled steroids (low dose) or cromolyn or nedocromil Sustained release theophylline alternative but not preferred
  • 51.  Mild persistent asthma (step 2 care)   Zafirlukast or zileuton considered in pts. >12 yrs Quick relief medications must be available  short-acting beta 2 agonists  intensity depends upon severity of exacerbation
  • 52.  Moderate persistent asthma (step 3 care) Increase inhaled steroids to medium dose OR  Add long-acting bronchodilator to a low-medium dose of inhaled steroids OR  Increase to medium dose steroid then lower dose & add nedocromil (+/-) 
  • 53.  Moderate persistent asthma (if not adequately controlled)  Increase to high dose inhaled steroids & add longacting bronchodilator (serevent or theophylline)
  • 54.  Severe persistent asthma (step 4)  If not controlled on high dose of inhaled steroids and long-acting bronchodilator ADD oral systemic steroids on a regularly scheduled, longterm basis use lowest dose  monitor closely  attempt to reduce or take off when control established 
  • 55. Emergency Department Treatment   Start treatment when asthma exacerbation recognized While treatment is being given:    Take a more detailed history Complete physical examination Perform laboratory studies  PEF on presentation, after initial tx. and at frequent intervals)
  • 56.  Perform laboratory studies FEV1 or PEF <50% pred. then assess oxygenation by pulse oximetry  Lab studies will vary with situation (CBC, electrolytes, serum theophylline level. CXR, ECG). These lab studies are NOT routinely recommended 
  • 57.  Treatment:  O2 (Sa O2 90-95), inhaled short-acting bronchodilator for all pts. (3 tx Q 20 min, continuous therapy an option)  Consider anti-cholinergics  oral systemic corticosteroids (unresponsive to initial beta2 agonist therapy, moderate-to-severe asthma, people who are on steroids)  systemic steroids administered when admitted  methylxanthines are not recommended 
  • 58.  Treatment: Aggressive hydration NOT recommended for older children and adults (may be necessary with infants and sm. children)  Antibiotics NOT recommended unless infection present (fever, purulent sputum)  CPT NOT recommended  Mucolytics NOT recommended  Sedation NOT recommended 
  • 59. Long-Term, Control Medications Decrease the inflammation/swelling Advair
  • 60. Quick R elief Medications Loosens your muscles & stops the wheezing Albuterol for Nebulizer
  • 63. Why Control Asthma? •Mild intermittent •Mild persistent •Moderate persistent •Severe persistent

Editor's Notes

  • #60: These medicines reduce inflammation and mucus production. They do nothing for bronchospasm. Do not use them for quick relief of symptoms. Take these medications EVERYDAY even if you feel OK. Advair is a new combination medicine of Flovent and Serevent. Flovent is a corticosteroid and Serevent is a long-acting bronchodilator. Neither medicine is for quick relief of symptoms.
  • #61: These medications relax the muscles, but they do nothing for inflammation and swelling. All the pictured medicines do the same thing. Keeping various of these meds in different locations is OK, but they shouldn’t all be used to treat a flare-up at the same time. Albuterol, Ventolin, Proventil all are different brand names of the same medicine: Albuterol. Maxair inhaler is pirbuterol(similar to Albuterol. Works the same as Albuterol) This is a breath-actuated inhaler so it’s good for kids who won’t carry spacers. However, insurance doesn’t cover it so we don’t see it much. Xopenex is a brand that contains lev-albuterol (no isomer - works the same as Albuterol, but they say it doesn’t cause side effects). This is only available as a nebulizer treatment.
  • #62: Spacers come in many shapes and sizes. The only bad spacer is the one that isn’t used. All people with asthma, adults and children, should be using spacers.
  • #63: These pictures show how medication is deposited in the lungs when using or not using a spacer. An MDI discharges medicine at 45 miles per hour. Spacers slow the medicine down to facilitate inhalation. Without a spacer much of the medicine falls on the mouth and the back of the throat. Then it is swallowed to the stomach and absorbed into the blood stream. When Albuterol gets into the blood stream, it can cause jitters. (A placebo inhaler can be passed around so that the audience can feel how hard it is to inhale medicine from an MDI without a spacer.) When using a spacer, most of the medicine gets into the lungs. Very little reaches the blood stream, so side effects are minimized.
  • #64: This picture can be used to describe asthma categories: Mild intermittent Mild persistent Moderate persistent Severe persistent All categories have the same risk of death. People with mild asthma often think “it’s mild, so I don’t have to worry about it”. These are the same people who have the most severe asthma attacks. Use this picture to describe what happens if you stop taking long-term control medications. If you take quick relief medication at the onion ring stage, your muscles will relax and your airways will go back to normal. If you take a quick relief med at the bagel stage, the muscles will relax, but your airway will only go back to bagel…..This is how people get used to compromised breathing. Take control medications everyday, even if you feel OK.